Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 2/6 |
Past Performance | 5/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for RX3 from our risk checks.
REX American Resources Corporation Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$45.20 |
52 Week High | US$56.00 |
52 Week Low | US$33.20 |
Beta | 0.94 |
11 Month Change | 7.62% |
3 Month Change | 11.88% |
1 Year Change | 32.16% |
33 Year Change | 79.60% |
5 Year Change | 65.37% |
Change since IPO | 1,376.29% |
Recent News & Updates
Recent updates
Shareholder Returns
RX3 | DE Oil and Gas | DE Market | |
---|---|---|---|
7D | 11.9% | -2.7% | 1.1% |
1Y | 32.2% | -35.4% | 13.5% |
Return vs Industry: RX3 exceeded the German Oil and Gas industry which returned -34.6% over the past year.
Return vs Market: RX3 exceeded the German Market which returned 12.9% over the past year.
Price Volatility
RX3 volatility | |
---|---|
RX3 Average Weekly Movement | 4.7% |
Oil and Gas Industry Average Movement | 5.5% |
Market Average Movement | 4.7% |
10% most volatile stocks in DE Market | 10.8% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: RX3 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: RX3's weekly volatility (5%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1980 | 117 | Zafar Rizvi | www.rexamerican.com |
REX American Resources Corporation, together with its subsidiaries, produces and sells ethanol in the United States. The company also offers corn, distillers grains, ethanol, distillers corn oil, gasoline, and natural gas. In addition, it provides dry distillers grains with solubles, which is used as a protein in animal feed.
REX American Resources Corporation Fundamentals Summary
RX3 fundamental statistics | |
---|---|
Market cap | €799.69m |
Earnings (TTM) | €64.96m |
Revenue (TTM) | €673.99m |
12.4x
P/E Ratio1.2x
P/S RatioIs RX3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
RX3 income statement (TTM) | |
---|---|
Revenue | US$718.08m |
Cost of Revenue | US$614.16m |
Gross Profit | US$103.92m |
Other Expenses | US$34.71m |
Earnings | US$69.21m |
Last Reported Earnings
Jul 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 3.94 |
Gross Margin | 14.47% |
Net Profit Margin | 9.64% |
Debt/Equity Ratio | 0% |
How did RX3 perform over the long term?
See historical performance and comparison